ES2084347T3 - Derivados de 5-heteroil-indol. - Google Patents

Derivados de 5-heteroil-indol.

Info

Publication number
ES2084347T3
ES2084347T3 ES92904837T ES92904837T ES2084347T3 ES 2084347 T3 ES2084347 T3 ES 2084347T3 ES 92904837 T ES92904837 T ES 92904837T ES 92904837 T ES92904837 T ES 92904837T ES 2084347 T3 ES2084347 T3 ES 2084347T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
heteroil
indol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904837T
Other languages
English (en)
Spanish (es)
Inventor
Jolanta Teresa Nowakowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2084347T3 publication Critical patent/ES2084347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES92904837T 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol. Expired - Lifetime ES2084347T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12

Publications (1)

Publication Number Publication Date
ES2084347T3 true ES2084347T3 (es) 1996-05-01

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904837T Expired - Lifetime ES2084347T3 (es) 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol.

Country Status (24)

Country Link
EP (1) EP0571471B1 (2)
JP (1) JPH07121942B2 (2)
KR (1) KR930703305A (2)
AT (1) ATE135005T1 (2)
AU (1) AU655456B2 (2)
CA (1) CA2101521A1 (2)
CZ (1) CZ165693A3 (2)
DE (1) DE69208868T2 (2)
DK (1) DK0571471T3 (2)
ES (1) ES2084347T3 (2)
FI (1) FI933551A7 (2)
GR (1) GR3019778T3 (2)
HU (1) HUT65766A (2)
IE (1) IE920442A1 (2)
IL (1) IL100888A0 (2)
MX (1) MX9200569A (2)
MY (1) MY131298A (2)
NO (1) NO932859D0 (2)
NZ (1) NZ241584A (2)
PT (1) PT100114A (2)
TW (1) TW263508B (2)
WO (1) WO1992013856A1 (2)
YU (1) YU13792A (2)
ZA (1) ZA92969B (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (2) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
JP3262800B2 (ja) * 1994-06-01 2002-03-04 ゼネカ・リミテッド 療用複素環化合物
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
AU702322B2 (en) * 1995-03-20 1999-02-18 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
JP2002506069A (ja) 1998-03-09 2002-02-26 ハー・ルンドベック・アクチエゼルスカベット 5−ヘテロアリール置換されたインドール類
DE69912279T2 (de) * 1998-06-30 2004-07-29 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
ES2291024T4 (es) * 1999-04-21 2009-03-01 Nps Allelix Corp. Compuestos de piperidina-indol con afinidad con 5-ht6.
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
AU9619301A (en) * 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
AU2003239508A1 (en) 2002-05-21 2003-12-12 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
US7875605B2 (en) * 2002-11-28 2011-01-25 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗hcv作用を有する縮合ヘテロ環化合物
JP5833804B2 (ja) 2005-04-13 2015-12-16 ニューラクソン,インコーポレーテッド Nos阻害活性を有する置換インドール化合物
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
AU2007240078B2 (en) 2006-04-13 2013-07-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
JP2010500372A (ja) * 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
KR20100103799A (ko) 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションLycera Corporation RORγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2017075185A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017075182A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
US4833153A (en) * 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
KR100215627B1 (ko) * 1990-06-07 1999-08-16 레슬리 제인 에드워즈 치료용 헤테로사이클 화합물

Also Published As

Publication number Publication date
YU13792A (sh) 1994-11-15
IE920442A1 (en) 1992-08-12
NO932859L (no) 1993-08-11
NO932859D0 (no) 1993-08-11
GR3019778T3 (en) 1996-07-31
EP0571471B1 (en) 1996-03-06
AU1263792A (en) 1992-09-07
FI933551A0 (fi) 1993-08-11
DE69208868T2 (de) 1996-10-17
MX9200569A (es) 1992-08-01
IL100888A0 (en) 1992-11-15
DK0571471T3 (da) 1996-04-01
FI933551L (fi) 1993-08-11
NZ241584A (en) 1994-12-22
KR930703305A (ko) 1993-11-29
ATE135005T1 (de) 1996-03-15
TW263508B (2) 1995-11-21
HUT65766A (en) 1994-07-28
DE69208868D1 (de) 1996-04-11
FI933551A7 (fi) 1993-08-11
JPH06500122A (ja) 1994-01-06
MY131298A (en) 2007-08-30
CZ165693A3 (en) 1994-05-18
WO1992013856A1 (en) 1992-08-20
PT100114A (pt) 1993-05-31
AU655456B2 (en) 1994-12-22
HU9302328D0 (en) 1993-10-28
EP0571471A1 (en) 1993-12-01
ZA92969B (en) 1993-08-11
CA2101521A1 (en) 1992-08-13
JPH07121942B2 (ja) 1995-12-25

Similar Documents

Publication Publication Date Title
MX9200569A (es) Derivados de 5-heteroil indol.
ES8603711A1 (es) Procedimiento para preparar compuestos benzimidazoles 2-piridilmetil-tio y sulfinil substituidos
ES2066991T3 (es) Agentes hipoglucemiantes de oxazolidinadiona.
ES8406429A1 (es) &#34;un metodo de preparacion de nuevas sulfonamidas sustituidas&#34; nota: se solicita como divisional de la patente de invencion n 516.504.
ATE31307T1 (de) Benzofuran- und benzopyrancarboxamid-derivate.
NZ332559A (en) 3-mercapto-propylamine substituted 4-carbonylamino-5,5-dimethyl-thiazolidine derivatives
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
NZ528997A (en) Sulfonamides
ATE237612T1 (de) Benzofuranderivate
DK429089A (da) Alkylbenzylaminer
UY24010A1 (es) Nuevos pirrolocarbazoles
ES2001106A6 (es) Procedimiento para la obtencion de 1-aril-pirazoles
PE14696A1 (es) Derivado de fenetanolamina
ES2064618T3 (es) Agonistas de serotonina de tetrahidrobenz(c,d)indol.
NO902336D0 (no) Antispasmotiske midler.
PE14896A1 (es) Aminoalcanimidazoles y triazoles acilados
AR247735A1 (es) Sulfonildiamidas sustituidas, procedimientos para su preparacion, intermediarios utilizados en el procedimiento, y su utilizacion como herbicidas y reguladoras del crecimiento de las plantas
PT87048A (pt) Process for preparing benzazepine sulfonamides antiarrhythmic agents
ES2092112T3 (es) Agentes hipoglicemicos de tiazolidindiona.
CO4410332A1 (es) Oxazoles y tiazoles sustituidos
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.
DE3662268D1 (de) Subsitued furazans
US4010175A (en) Thio-{62 -lactam penicillins
ES2097319T3 (es) Derivados de isoxazol como agentes protectores de la luz.
ECSP951529A (es) Compuestos farmaceuticos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 571471

Country of ref document: ES